Healthcare / BiotechnologyNasdaqCM
$1.85
+0.02 (+1.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-135.3M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$559M
P/E
N/A
•EV/EBITDA
N/A
•ROE
6.8%
↑Gross Margin
N/A
•Debt/Equity
-0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-15152.6%
FCF / Net income
1.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $893000.0 · net income $-69.0M · FCF $-135.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $893000.00 | $893000.00 | $76000.00 | — | — | — | — |
| Net Income | $-69.0M | $-69.0M | $-61.2M | $-35.5M | $-108.0M | $-55.1M | $-26.7M |
| EBITDA | $-144.6M | $-144.6M | $-158.5M | $-125.6M | $-144.0M | $-53.1M | $-26.1M |
| EPS | -0.52 | -0.52 | -0.62 | -0.57 | -0.23 | — | — |
| Operating Margin | -18477.8% | -18477.8% | -241678.9% | — | — | — | — |
| Net Margin | -7725.2% | -7725.2% | -80507.9% | — | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | — | — |
| Current Ratio | 9.06 | 9.06 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-135.3M | $-135.3M | $-155.9M | $-124.3M | $-78.9M | $-55.5M | $-30.6M |
| Returns | |||||||
| ROE | 6.8% | 6.8% | 6.1% | 3.2% | 9.9% | -204.9% | -271.2% |
| Growth & Yield | |||||||
| Revenue Growth | 1075.0% | 1075.0% | — | — | — | — | — |
| EPS Growth | 16.1% | 16.1% | -8.8% | -147.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+155.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.62 → -0.52
Residual
+155.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.